Aqsa Maimoona Malik

Dr. Aqsa Maimoona Malik


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2025 in UCP Journal of Science & Technology
Verified
Journal Article
Open access
PDF file
KHKhalid Hussain
Khalid Hussain
AMAqsa Maimoona Malik
Aqsa Maimoona Malik
One of the leading causes of death in Hemodialysis (HD) patients is Cytomegalovirus(CMV) infection. Quantitative PCR is considered as a highly sensitive method as itdetects small quantities of nucleic acid in various clinical samples. In Pakistan,nephrology units are not well developed and the investigations involved in normalencounter of viral infections in HD patients have been quite limited. Present study aimedto determine the prevalence of CMV infection, by ELISA and qPCR in patientsundergoing HD, in nephrology units in Pakistan. In this cross-sectional study total 150patients undergoing HD were included by non-probability convenience samplingtechnique, and those undergoing peritoneal dialysis were excluded. Blood specimen wascollected to estimate Hb, TLC, PLT count, bilirubin total, AST, ALT, ALP, urea,creatinine, uric acid and glucose levels. CMV IgM and IgG antibodies were detected byELISA method and CMV viral load by qPCR. Data was analyzed by using SPSS v.26.Mean of age was found to be 42.28±13.63 years, CMV IgM antibodies level=323±210AU/mL and CMV IgG antibodies level=311±182 AU/mL. Overall patients’ frequency ofmale was 66.7% and of female was 33.3%. Frequency of patients with positive CMV IgMlevel was 43.3%, positive CMV IgG level 72.0%, and positive for CMV viral load 82.7%.Prevalence of CMV IgM infection was higher in younger age (45.1% vs. 40.7%), males(45.0% vs. 40.0%), anemic males (46.0% vs. 38.5%), leukocytosis (55.6% vs. 50.0%),thrombocytopenia (32.0% vs. 18.2%). Prevalence of CMV IgG infection was also higherin younger age (74.7% vs. 67.8%), anemic males (73.6% vs. 61.5%), anemic females(73.2% vs. 66.7%), and leukocytosis (80.0% vs. 75.0%). Prevalence of CMV viral loadwas lower in younger age (81.3% vs. 84.7%, P-value 0.748); males (81.0% vs. 86.0%, Pvalue0.593); non-anemic males (76.9% vs. 81.6%, P-value 0.708), leukocytosis (93.3%vs. 100.0%, P-value 0.019), bilirubin total >1.0 (80.4% vs. 83.8%, and BSR (78.7% vs.88.5%, P-value 0.177). The study concluded that prevalence of positive CMV viral loadwas markedly higher than prevalence of CMV IgG positive cases and almost twice higherthan CMV IgM positive cases. Screening for CMV infection by commonly used ELISAmethod may give false negative results. Therefore, patients undergoing HD should bescreened by quantitative PCR in future.

10 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Ghulam Jilany KhanGhulam Jilany Khan
Ghulam Jilany Khan
AMAqsa Maimoona Malik
Aqsa Maimoona Malik
Cancer is a lethal disease worldwide that damages bodily tissues, linked with predisposing variables including inheritance, social, infections and curative measures requiring behavioral modifications. But now a days, researchers are working to find targeted drug therapy with limited side effects that are associated with previous approaches. Plant based novel drug Halofuginone (HaF), by blocking prolyl tRNA synthetase exhibits promising diverse clinical activities, against fibrosis, cancer, metabolic, and infectious disorders. However, the drug is quite neurotoxic and gastrotoxic requiring thorough investigational analyses as per preclinical studies at Phase-II clinical trials. The present study explored various databases, software and monographs to establish therapeutic aspects of this drug to address gaps by highlighting the potential impact of salt reformation on improving its properties. Hence, our study invites the researchers to look upon novel Halofuginone derivatives with other possible halogen salts like HCl to enhance pharmacokinetics and pharmacodynamics qualities of Halofuginone. Our present study summaries the possibilities of other form of Halofuginone for safe utility in pharmacotherapeutics for future research in this area, provided its toxicity concerns are adequately addressed through innovative strategies.